stoxline Quote Chart Rank Option Currency Glossary
Revolution Medicines, Inc. (RVMD)
23.52  -0.71 (-2.93%)    12-05 16:00
Open: 24.02
High: 24.085
Volume: 1,219,931
Pre. Close: 24.23
Low: 23.38
Market Cap: 2,577(M)
Technical analysis
2023-12-05 4:22:36 PM
Short term     
Mid term     
Targets 6-month :  28.97 1-year :  33.83
Resists First :  24.8 Second :  28.97
Pivot price 22.14
Supports First :  20.59 Second :  18
MAs MA(5) :  23.6 MA(20) :  21.7
MA(100) :  26.92 MA(250) :  25.52
MACD MACD :  0.1 Signal :  -0.5
%K %D K(14,3) :  86.5 D(3) :  91.2
RSI RSI(14): 54.8
52-week High :  35.59 Low :  15.43
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ RVMD ] has closed below upper band by 20.2%. Bollinger Bands are 38.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 24.11 - 24.24 24.24 - 24.35
Low: 23.06 - 23.23 23.23 - 23.36
Close: 23.27 - 23.52 23.52 - 23.73
Company Description

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Headline News

Fri, 17 Nov 2023
A great week that adds to Revolution Medicines, Inc.'s (NASDAQ:RVMD) one-year returns, institutional investors who ... - Yahoo Finance

Tue, 14 Nov 2023
Should You Hold Revolution Medicines Inc (RVMD) Stock Tuesday? - InvestorsObserver

Mon, 13 Nov 2023
Do Traders Think Revolution Medicines Inc (RVMD) Can Turn Around Monday? - InvestorsObserver

Tue, 07 Nov 2023
Revolution Medicines, Inc. (NASDAQ:RVMD) Q3 2023 Earnings Call Transcript - Yahoo Finance

Mon, 06 Nov 2023
Revolution Medicines Inc (RVMD) Reports Q3 2023 Financial Results and Corporate Progress - Yahoo Finance

Thu, 26 Oct 2023
Revolution Medicines Inc Shares Close the Week 31.3% Lower - Weekly Wrap - Nasdaq

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 164 (M)
Held by Insiders 1.0697e+008 (%)
Held by Institutions 1.7 (%)
Shares Short 10,870 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.641e+008
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -1 %
Return on Assets (ttm) 409.7 %
Return on Equity (ttm) -25.5 %
Qtrly Rev. Growth 2.617e+007 %
Gross Profit (p.s.) 0
Sales Per Share -29.69
EBITDA (p.s.) -1.48088e+008
Qtrly Earnings Growth -3.3 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -292 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.8
Price to Cash Flow 4.51
Stock Dividends
Dividend 0
Forward Dividend 1.625e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android